SYM FINANCIAL Corp Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

SYM FINANCIAL Corp lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 32.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,559 shares of the biopharmaceutical company’s stock after selling 6,924 shares during the period. SYM FINANCIAL Corp’s holdings in Pfizer were worth $369,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Providence Capital Advisors LLC boosted its holdings in Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after acquiring an additional 409 shares in the last quarter. William B. Walkup & Associates Inc. raised its position in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co lifted its holdings in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 467 shares in the last quarter. Sutton Place Investors LLC grew its position in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 472 shares during the period. Finally, Bellevue Group AG increased its stake in Pfizer by 0.3% during the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock valued at $3,756,000 after purchasing an additional 485 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on PFE shares. Leerink Partners lowered their price objective on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 30th. Bank of America boosted their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. TD Cowen decreased their price objective on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a report on Tuesday, April 22nd. Citigroup raised their price target on Pfizer from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, HSBC lowered their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.55.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.32 on Thursday. The company has a 50-day simple moving average of $24.20 and a two-hundred day simple moving average of $24.71. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market capitalization of $143.98 billion, a PE ratio of 18.35, a P/E/G ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.79%. The ex-dividend date is Friday, July 25th. Pfizer’s payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.